Stock Track | REMEGEN Soars 8.36% as Company Secures 11 Presentations at ESMO 2025, Including Late-Breaking Abstract

Stock Track

Sep 25

REMEGEN (09995.HK) saw its stock price soar 8.36% in intraday trading on Thursday, as investors reacted positively to the company's announcement regarding its significant presence at the upcoming European Society for Medical Oncology (ESMO) 2025 annual meeting.

The biopharmaceutical company revealed that it has secured the inclusion of 11 original research results at the prestigious conference, scheduled to take place in Berlin, Germany from October 17-21. Notably, REMEGEN's RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for the coveted "Late-Breaking Abstracts (LBA)" category, underscoring the study's academic importance and potential impact on cancer treatment.

In addition to the late-breaking presentation, REMEGEN will showcase 10 other studies at ESMO 2025, including two short oral presentations and eight poster presentations. These studies span multiple tumor types and treatment strategies, covering areas such as urothelial carcinoma, gastric cancer, and gynecological tumors. This comprehensive showcase is seen as a strong indication of REMEGEN's leading position in Antibody-Drug Conjugate (ADC) therapies and combination treatments, likely contributing to the positive market sentiment and the subsequent stock price surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1122272627"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122272627\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122272627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122272627","market":"hk","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 8.36% as Company Secures 11 Presentations at ESMO 2025, Including Late-Breaking Abstract","media":"Stock Track","content":"<p>REMEGEN (09995.HK) saw its stock price soar 8.36% in intraday trading on Thursday, as investors reacted positively to the company's announcement regarding its significant presence at the upcoming European Society for Medical Oncology (ESMO) 2025 annual meeting.</p>\n\n<p>The biopharmaceutical company revealed that it has secured the inclusion of 11 original research results at the prestigious conference, scheduled to take place in Berlin, Germany from October 17-21. Notably, REMEGEN's RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for the coveted \"Late-Breaking Abstracts (LBA)\" category, underscoring the study's academic importance and potential impact on cancer treatment.</p>\n\n<p>In addition to the late-breaking presentation, REMEGEN will showcase 10 other studies at ESMO 2025, including two short oral presentations and eight poster presentations. These studies span multiple tumor types and treatment strategies, covering areas such as urothelial carcinoma, gastric cancer, and gynecological tumors. This comprehensive showcase is seen as a strong indication of REMEGEN's leading position in Antibody-Drug Conjugate (ADC) therapies and combination treatments, likely contributing to the positive market sentiment and the subsequent stock price surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 8.36% as Company Secures 11 Presentations at ESMO 2025, Including Late-Breaking Abstract</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 8.36% as Company Secures 11 Presentations at ESMO 2025, Including Late-Breaking Abstract\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-25 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995.HK) saw its stock price soar 8.36% in intraday trading on Thursday, as investors reacted positively to the company's announcement regarding its significant presence at the upcoming European Society for Medical Oncology (ESMO) 2025 annual meeting.</p>\n\n<p>The biopharmaceutical company revealed that it has secured the inclusion of 11 original research results at the prestigious conference, scheduled to take place in Berlin, Germany from October 17-21. Notably, REMEGEN's RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for the coveted \"Late-Breaking Abstracts (LBA)\" category, underscoring the study's academic importance and potential impact on cancer treatment.</p>\n\n<p>In addition to the late-breaking presentation, REMEGEN will showcase 10 other studies at ESMO 2025, including two short oral presentations and eight poster presentations. These studies span multiple tumor types and treatment strategies, covering areas such as urothelial carcinoma, gastric cancer, and gynecological tumors. This comprehensive showcase is seen as a strong indication of REMEGEN's leading position in Antibody-Drug Conjugate (ADC) therapies and combination treatments, likely contributing to the positive market sentiment and the subsequent stock price surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1122272627","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122272627","pubTimestamp":1758765741,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995.HK) saw its stock price soar 8.36% in intraday trading on Thursday, as investors reacted positively to the company's announcement regarding its significant presence at the upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"股票追踪|REMEGEN飙升8.36%，公司在ESMO 2025上获得11场演讲，包括最新摘要","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995.HK) saw its stock price soar 8.36% in intraday trading on Thursday, as investors reacted positively to the company's announcement regarding its significant presence at the upcoming European Society for Medical Oncology (ESMO) 2025 annual meeting.\nThe biopharmaceutical company revealed that it has secured the inclusion of 11 original research results at the prestigious conference, scheduled to take place in Berlin, Germany from October 17-21. Notably, REMEGEN's RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for the coveted \"Late-Breaking Abstracts (LBA)\" category, underscoring the study's academic importance and potential impact on cancer treatment.\nIn addition to the late-breaking presentation, REMEGEN will showcase 10 other studies at ESMO 2025, including two short oral presentations and eight poster presentations. These studies span multiple tumor types and treatment strategies, covering areas such as urothelial carcinoma, gastric cancer, and gynecological tumors. This comprehensive showcase is seen as a strong indication of REMEGEN's leading position in Antibody-Drug Conjugate (ADC) therapies and combination treatments, likely contributing to the positive market sentiment and the subsequent stock price surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}